887266-90-2

Basic information

• Product Name: 3-Bromo-5-fluorobenzoyl chloride
• Synonyms: Benzoyl chloride, 3-bromo-5-fluoro-
• CAS NO: 887266-90-2
• Molecular Formula: C₇H₃BrClFO
• Molecular Weight: 237.46
• Product Categories: Fluorine series
• Mol File: 887266-90-2.mol

Chemical Properties

• Boiling Point: 250℃
• Flash Point: 105℃
• Appearance: /
• Density: 1.742
• Vapor Pressure: 0.0221mmHg at 25°C
• Refractive Index: 1.561
• CAS DataBase Reference: 3-Bromo-5-fluorobenzoyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Bromo-5-fluorobenzoyl chloride(887266-90-2)
• EPA Substance Registry System: 3-Bromo-5-fluorobenzoyl chloride(887266-90-2)

Safety Data

• Hazardous Substances Data: 887266-90-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Bromo-5-fluorobenzoyl chloride is used as a key intermediate for the synthesis of novel pharmaceutical products. Its high reactivity allows for the development of new compounds with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical industry, 3-Bromo-5-fluorobenzoyl chloride is utilized as a building block for the creation of new agrochemicals, contributing to the development of innovative products for agricultural use.
Used as a Reagent in Organic Synthesis:
3-Bromo-5-fluorobenzoyl chloride is employed as a reagent in organic synthesis, facilitating various chemical reactions and contributing to the synthesis of a wide range of organic compounds.
Used in the Production of Fine Chemicals:
3-Bromo-5-fluorobenzoyl chloride is also used in the production of fine chemicals, where its reactivity and properties are leveraged to create high-quality specialty chemicals for various applications.
It is important to handle 3-Bromo-5-fluorobenzoyl chloride with care and store it in a cool, dry place away from heat and direct sunlight to ensure its stability and reactivity.

InChI:InChI=1/C7H3BrClFO/c8-5-1-4(7(9)11)2-6(10)3-5/h1-3H

Upstream product

• 176548-70-2 3-bromo-5-fluorobenzoic acid 
• 179898-34-1 3-bromo-5-fluorobenzonitrile 
• 1435-51-4 1,3-dibromo-5-fluorobenzene 

Downstream Products

• 1042498-29-2 3-bromo-5-fluoro-N-(6-methylpyridin-2-yl)benzamide 

Relevant articles and documents

SYNTHESIS, CRYSTAL STRUCTURE, AND DFT STUDY OF METHYL 3-FLUORO-5-(4,4,5,5-TETRAMETHYL-1,3,2- DIOXABOROLAN-2-YL)BENZOATE AND (2-METHYL-4- (4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL) PHENYL)(PYRROLIDIN-1-YL)METHANONE COMPOUNDS

Abstract: Methyl 3-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate and (2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)(pyrrolidin-1-yl)methanone are boric acid ester intermediates with benzene rings. In this paper, the titl

BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS

The invention provides biomarkers to predict effective treatment of cancer using an MDM2 antagonist. Identifying one or more of these biomarkers in a cancer patient allows a determination to be made whether the patient's cancer is likely to be successfully treated using an MDM2 antagonist. Accordingly, the invention relates generally to a companion diagnostic for MDM2 antagonist therapy. The biomarkers are: (i) BAP1; and/or (ii) CDKN2A; and/or (iii) one, two, three, four, five, six, seven, eight, nine, ten or more of: CXCL10, CXCL11, RSAD2, MX1, BATF2, IFI44L, IFITM1, ISG15, CMPK2, IFI27, CD74, IFIH1, CCRL2, IFI44, HERC6, ISG20, IFIT3, HLA-C, OAS1, IFI35, IRF9, EPSTI1, USP18, BST2, CSF1, C1S, DHX58, TRIM14, OASL, IRF7, LGALS3BP, DDX60, LAP3, LAMP3, PARP12, PARP9, SP110, PLSCR1, WARS, STAT1, IRF3, IRF5, MSC, JUN, SPI1, IRF1, COMMD3-BMI1, STAT2, RUNX3, SREBF1, FLI1 and BRCA1.

ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM

The invention relates to processes for preparing isoindolin-1-one derivatives, and in particular processes for preparing (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1- (oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-

PIPERIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS

Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

BIARYL-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS

The present invention relates to compounds of the formula (I), wherein X, R, R1, R2, D, E1, E2, E3, E4, G1, G2, G3 and G4 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease ca

Biaryl-propionic acid derivatives and their use as pharmaceuticals

The present invention relates to compounds of the formula I, wherein X, R, R1, R2, D, E1, E2, E3, E4, G1, G2, G3 and G4 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cath

BIARYL-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS

The present invention relates to compounds of the formula (I), wherein X, R, R1, R2, D, E1, E2, E3, E4, G1, G2, G3 and G4 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease ca

Biaryl-Propionic Acid Derivatives and their Use as Pharmaceuticals

The present invention relates to compounds of the formula I, wherein X, R, R1, R2, D, E1, E2, E3, E4, G1, G2, G3 and G4 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cath

AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES

The invention provides novel compounds having the general formula: wherein A, R1, R2 and R3 are as defined herein, compositions including the compounds and methods of using the compounds.

Discovery and characterization of AZD9272 and AZD6538 - Two novel mGluR5 negative allosteric modulators selected for clinical development

AZD9272 and AZD6538 are two novel mGluR5 negative allosteric modulators selected for further clinical development. An initial high-throughput screening revealed leads with promising profiles, which were further optimized by minor, yet indispensable, structural modifications to bring forth these drug candidates. Advantageously, both compounds may be synthesized in as little as one step. Both are highly potent and selective for the human as well as the rat mGluR5 where they interact at the same binding site than MPEP. They are orally available, allow for long interval administration due to a high metabolic stability and long half-lives in rats and permeate the blood brain barrier to a high extent. AZD9272 has progressed into phase I clinical studies.